Related references
Note: Only part of the references are listed.Pluripotent stem cell-derived hepatocyte-like cells
R. E. Schwartz et al.
BIOTECHNOLOGY ADVANCES (2014)
Evaluation of Various Static In Vitro-In Vivo Extrapolation Models for Risk Assessment of the CYP3A Inhibition Potential of an Investigational Drug
Md L. T. Vieiral et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Evaluation of Various Static and Dynamic Modeling Methods to Predict Clinical CYP3A Induction Using In Vitro CYP3A4 mRNA Induction Data
H. J. Einolfl et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Quantitative Prediction of Transporter- and Enzyme-Mediated Clinical Drug-Drug Interactions of Organic Anion-Transporting Polypeptide 1B1 Substrates Using a Mechanistic Net-Effect Model
Manthena V. Varma et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Evaluation of Calibration Curve-Based Approaches to Predict Clinical Inducers and Noninducers of CYP3A4 with Plated Human Hepatocytes
J. George Zhang et al.
DRUG METABOLISM AND DISPOSITION (2014)
A Numerical Method for Analysis of In Vitro Time-Dependent Inhibition Data. Part 1. Theoretical Considerations
Swati Nagar et al.
DRUG METABOLISM AND DISPOSITION (2014)
A Numerical Method for Analysis of In Vitro Time-Dependent Inhibition Data. Part 2. Application to Experimental Data
Ken Korzekwa et al.
DRUG METABOLISM AND DISPOSITION (2014)
In Vitro Assessment of Time-Dependent Inhibitory Effects on CYP2C8 and CYP3A Activity by Fourteen Protein Kinase Inhibitors
Anne M. Filppula et al.
DRUG METABOLISM AND DISPOSITION (2014)
Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach
Marco Siccardi et al.
CLINICAL PHARMACOKINETICS (2013)
Modeling of Rifampicin-Induced CYP3A4 Activation Dynamics for the Prediction of Clinical Drug-Drug Interactions from In Vitro Data
Fumiyoshi Yamashita et al.
PLOS ONE (2013)
Optimization of Drug-Drug Interaction Study Design: Comparison of Minimal Physiologically Based Pharmacokinetic Models on Prediction of CYP3A Inhibition by Ketoconazole
Bing Han et al.
DRUG METABOLISM AND DISPOSITION (2013)
Quantitative Prediction of Repaglinide-Rifampicin Complex Drug Interactions Using Dynamic and Static Mechanistic Models: Delineating Differential CYP3A4 Induction and OATP1B1 Inhibition Potential of Rifampicin
Manthena V. S. Varma et al.
DRUG METABOLISM AND DISPOSITION (2013)
Assessment of drug-drug interactions caused by metabolism-dependent cytochrome P450 inhibition
Ji-Yoon Lee et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2012)
Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates - An evaluation and case study using GastroPlus™
Aki T. Heikkinen et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2012)
Drug-Drug Interaction Potential of Marketed Oncology Drugs: In Vitro Assessment of Time-Dependent Cytochrome P450 Inhibition, Reactive Metabolite Formation and Drug-Drug Interaction Prediction
Jane R. Kenny et al.
PHARMACEUTICAL RESEARCH (2012)
Statistical Methods for Analysis of Time-Dependent Inhibition of Cytochrome P450 Enzymes
Phillip Yates et al.
DRUG METABOLISM AND DISPOSITION (2012)
Predictions of Cytochrome P450-Mediated Drug-Drug Interactions Using Cryopreserved Human Hepatocytes: Comparison of Plasma and Protein-Free Media Incubation Conditions
Jialin Mao et al.
DRUG METABOLISM AND DISPOSITION (2012)
Identification of Clinically Used Drugs That Activate Pregnane X Receptors
Sunita J. Shukla et al.
DRUG METABOLISM AND DISPOSITION (2011)
CYP3A Time-Dependent Inhibition Risk Assessment Validated with 400 Reference Drugs
Alfred Zimmerlin et al.
DRUG METABOLISM AND DISPOSITION (2011)
Prediction of CYP3A-Mediated Drug-Drug Interactions Using Human Hepatocytes Suspended in Human Plasma
Jialin Mao et al.
DRUG METABOLISM AND DISPOSITION (2011)
A Refined Cytochrome P540 IC50 Shift Assay for Reliably Identifying CYP3A Time-Dependent Inhibitors
Ping Li et al.
DRUG METABOLISM AND DISPOSITION (2011)
Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: Impact of inactivation parameters and enzyme turnover
K. Rowland Yeo et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2011)
Integrated in Silico-in Vitro Strategy for Addressing Cytochrome P450 3A4 Time-Dependent Inhibition
Michael Zientek et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2010)
Predictions of Metabolic Drug-Drug Interactions Using Physiologically Based Modelling Two Cytochrome P450 3A4 Substrates Coadministered with Ketoconazole or Verapamil
Nathalie Perdaems et al.
CLINICAL PHARMACOKINETICS (2010)
The Use of HepaRG and Human Hepatocyte Data in Predicting CYP Induction Drug-Drug Interactions via Static Equation and Dynamic Mechanistic Modelling Approaches
Ken Grime et al.
CURRENT DRUG METABOLISM (2010)
Confidence Assessment of the Simcyp Time-Based Approach and a Static Mathematical Model in Predicting Clinical Drug-Drug Interactions for Mechanism-Based CYP3A Inhibitors
Ying-Hong Wang
DRUG METABOLISM AND DISPOSITION (2010)
Cytochrome P450 3A4 mRNA Is a More Reliable Marker than CYP3A4 Activity for Detecting Pregnane X Receptor-Activated Induction of Drug-Metabolizing Enzymes
Odette A. Fahmi et al.
DRUG METABOLISM AND DISPOSITION (2010)
Contribution of Intestinal Cytochrome P450-Mediated Metabolism to Drug-Drug Inhibition and Induction Interactions
Aleksandra Galetin et al.
DRUG METABOLISM AND PHARMACOKINETICS (2010)
Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut-The effect of diltiazem on the time-course of exposure to triazolam
Karen Rowland Yeo et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2010)
Pluripotent stem cell derived hepatocyte like cells and their potential in toxicity screening
Sebastian Greenhough et al.
TOXICOLOGY (2010)
Semiphysiologically Based Pharmacokinetic Models for the Inhibition of Midazolam Clearance by Diltiazem and Its Major Metabolite
Xin Zhang et al.
DRUG METABOLISM AND DISPOSITION (2009)
Evaluation of Multiple in Vitro Systems for Assessment of CYP3A4 Induction in Drug Discovery: Human Hepatocytes, Pregnane X Receptor Reporter Gene, and Fa2N-4 and HepaRG Cells
Dermot F. McGinnity et al.
DRUG METABOLISM AND DISPOSITION (2009)
The Conduct of in Vitro Studies to Address Time-Dependent Inhibition of Drug-Metabolizing Enzymes: A Perspective of the Pharmaceutical Research and Manufacturers of America
Scott W. Grimm et al.
DRUG METABOLISM AND DISPOSITION (2009)
Comparison of Different Algorithms for Predicting Clinical Drug-Drug Interactions, Based on the Use of CYP3A4 in Vitro Data: Predictions of Compounds as Precipitants of Interaction
Odette A. Fahmi et al.
DRUG METABOLISM AND DISPOSITION (2009)
Mechanism-based inhibition of cytochrome P450 enzymes: An evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods
Kenneth H. Grime et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2009)
The Simcyp® Population-based ADME Simulator
Masoud Jamei et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2009)
Cytochrome P450 and chemical toxicology
F. Peter Guengerich
CHEMICAL RESEARCH IN TOXICOLOGY (2008)
Cytochrome P450 turnover: Regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions
Jiansong Yang et al.
CURRENT DRUG METABOLISM (2008)
Prediction of drug-drug interactions from in vitro induction data - Application of the relative induction score approach using cryopreserved human hepatocytes
Odette A. Fahmi et al.
DRUG METABOLISM AND DISPOSITION (2008)
Coordinated induction of drug transporters and phase I and II metabolism in human liver slices
P. Olinga et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2008)
Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions
Aleksandra Galetin et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2008)
Efficient assessment of the utility of immortalized Fa2N-4 cells for cytochrome P450 (CYP) induction studies using multiplex quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) and substrate cassette methodologies
J. R. Kenny et al.
XENOBIOTICA (2008)
HepaRG cells as an in vitro model for evaluation of cytochrome p450 induction in humans
Kajsa P. Kanebratt et al.
DRUG METABOLISM AND DISPOSITION (2008)
Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment
K. Venkatakrishnan et al.
XENOBIOTICA (2007)
Induction of hepatic cytochrome P450 enzymes:: methods, mechanisms, recommendations, and in vitro-in vivo correlations
N. J. Hewitt et al.
XENOBIOTICA (2007)
Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs
Aleksandra Galetin et al.
CURRENT DRUG METABOLISM (2007)
Human hepatocytes: Isolation, cryopreservation and applications in drug development
Albert P. Li
CHEMICO-BIOLOGICAL INTERACTIONS (2007)
Time-dependent CYP inhibition
Robert J. Riley et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2007)
Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions
R. Scott Obach et al.
DRUG METABOLISM AND DISPOSITION (2007)
The time to move cytochrome P450 induction into mainstream pharmacology is long overdue
Dennis A. Smith et al.
DRUG METABOLISM AND DISPOSITION (2007)
Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction
Sharon L. Ripp et al.
DRUG METABOLISM AND DISPOSITION (2006)
Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes
Dermot F. McGinnity et al.
DRUG METABOLISM AND DISPOSITION (2006)
A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation
F Ghanbari et al.
CURRENT DRUG METABOLISM (2006)
Prediction of time-dependent CYP3A4 drug-drug interactions: Impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition
A Galetin et al.
DRUG METABOLISM AND DISPOSITION (2006)
CYP induction-mediated drug interactions: in vitro assessment and clinical implications
Jiunn H. Lin
PHARMACEUTICAL RESEARCH (2006)
Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs
SF Zhou et al.
CLINICAL PHARMACOKINETICS (2005)
A simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line
O Trubetskoy et al.
AAPS JOURNAL (2005)
Database analyses for the prediction of in vivo drug-drug interactions from in vitro data
K Ito et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites
YH Wang et al.
DRUG METABOLISM AND DISPOSITION (2004)
Time course of recovery of cytochrome P450 3A function after single doses of grapefruit juice
DJ Greenblatt et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes
K Ito et al.
DRUG METABOLISM AND DISPOSITION (2003)
A cell-based reporter gene assay for determining induction of CYP3A4 in a high-volume system
J Raucy et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Recent patterns of medication use in the ambulatory adult population of the United States - The Slone survey
DW Kaufman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Effect of grapefruit juice dose on grapefruit juice-triazolam interaction:: repeated consumption prolongs triazolam half-life
JJ Lilja et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2000)
Quantitative RT-PCR measurement of human cytochrome P-450s:: Application to drug induction studies
C Rodríguez-Antona et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2000)
Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model
H Takanaga et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2000)
Share Paper
